|Previous Section||Index||Home Page|
Tim Loughton: To ask the Secretary of State for Health how many people the Government estimates will be placed under compulsory community-based treatment orders under the provisions in the draft Mental Health Bill (a) once the Mental Health Bill is passed and (b) (i) five, (ii) 15 and (iii) 20 years after the Bill is passed. 
Ms Rosie Winterton: The Government's modelling assumption is that around 10 per cent. of treatment orders will be community based in the early years of the new Mental Health Act. In preparing for the introduction of the new Act, the focus should be on ensuring the appropriate use of community-based treatment by professionals, rather than arbitrarily defining numbers of those who should be subject to it.
Mr. Burstow: To ask the Secretary of State for Health pursuant to her answer to the hon. Member for South Cambridgeshire (Mr. Lansley) of 5 October 2005, Official Report, columns 283536W, on NHS Estates, what the (a) terms of reference and (b) timetable are forthe wider review of regulation in health and social care. 
I gave details of the wider review of regulation on 19 October 2005, Official Report, columns. 5657WS. The review will be conducted by officials from the Department of Health, with external scrutiny and challenge provided by a regulation review panel, comprising Lord Currie of Marylebone (chair), Dr. Dieter Helm of New College Oxford, and Mr. Robert Chilton, acting chair of the National Consumers Council. I shall provide a further update in the new year.
26 Oct 2005 : Column 442W
Mr. Paterson: To ask the Secretary of State for Health what the shortest time is that the National Institute for Health and Clinical Excellence has taken to approve a cancer drug having received formal approval from the European Medicines Evaluation Agency. 
Jane Kennedy: The shortest time the National Institute for Health and Clinical Excellence (NICE) has taken to approve a cancer drug, having received formal approval from the European Medicines Evaluation Agency (EMEA), was 11 months for leukaemia (chronic myeloid)imatinib. Imatinib was licensed by the EMEA on 1 November 2001 and NICE guidance was published in October 2002. A copy of this guidance is available on the NICE website at www.nice.org.uk
Mr. Laxton: To ask the Secretary of State for Health if her Department will refer to the National Institute for Health and Clinical Excellence the use of Herceptin to treat breast cancer in patients already diagnosed with the disease and who are at high risk of recurrence. 
Jane Kennedy: The Government have asked the National Institute for Health and Clinical Excellence (NICE) to conduct an appraisal of the clinical and cost effectiveness of Herceptin for the treatment of early stage breast cancer. Herceptin is not yet licensed for early stage breast cancer in England and NICE cannot complete its appraisal until the drug receives its license for this indication.
Mr. Lansley: To ask the Secretary of State for Health if she will list the services offered by Patientline to patients in NHS hospitals; what the cost of each service is, including the cost of making incoming calls to Patientline telephones; on which date Patientline first started supplying services to the NHS; which other suppliers of (a) televisions, (b) telephones and (c) other entertainment services have contracts to supply NHS trusts; and what assessment she has made of the degree of competition between suppliers in providing such services. 
|At least 16 television channels and bedside telephone||£3.50 per 24 hours|
|Concession for the over 60's||£1.70 per 24 hours|
|Concession for long stay patients (over two weeks)||£1.70 per 24 hours|
|All TV channels for children (under 16)||Free|
|One hour breakfast TV||Free|
|Hospital information channel||Free|
|Charge for the outgoing call from the patient's terminal||10 pence per minute (minimum 20 pence)|
|Internet and e-mail||Four pence per minute|
|Video games||30 pence each|
Incoming telephone call charges from United Kingdom landlines are 39 pence per minute off peak ratebetween 6 pm and 8 am Monday to Friday and all weekendand 49 pence per minute peak rateall other times. Patientline's calls to mobile phones and overseas calls vary in accordance with the network provider's terms and conditions.
The Office of Communications has opened an investigation into the provision of bedside communication and entertainment services recently installed in NHS hospitals under the Competition Act 1998. The Department is co-operating with this investigation.
Mr. Lansley: To ask the Secretary of State for Health what systems are in place to fast-track resubmissions of products to the Rapid Review Panel following their initial submission and rejection. 
Jane Kennedy: The supply chain excellence programme (SCEP) consists of four projects, one of which is national contracts procurements (NCP). This project is being conducted in two waves. All work carried out under the NCP project first has a full opportunity assessment and approval from the SCEP's departmental board. A regulatory impact assessment was not carried out for the whole of the second wave as it does not require any changes to existing Regulations and is consistent with the Department's objectives to improve efficiencies in the national health service supply chain.
Mr. Austin Mitchell:
To ask the Secretary of State for Health what (a) support, (b) advice, (c) legal costs,
26 Oct 2005 : Column 444W
(d) financial guarantees, (e) management time and (f) cover for additional costs are to be provided by her Department for the transfer of the South West London Orthopaedic Centre in Epsom to the private sector. 
Mr. Byrne [holding answer 17 October 2005]: The Department provides funding for the Stroke Association to conduct specific projects. They are currently receiving funding for a four year project, entitled, Stroke Prevention among South Asians". They will receive a total of £50,500 in four annual payments.
Mr. Holloway: To ask the Secretary of State for Health for what reasons Tarceva recently prescribed through an extended access programme is not available on the NHS; and when it will be available for patients on the NHS. 
|Next Section||Index||Home Page|